Antibodies News and Research

RSS

Early interferon therapy may mitigate COVID-19 severity

A recent review of COVID-19 therapies explores the utility of interferons in the battle against severe COVID-19, and concludes that they deserve further development.

26 Nov 2020

COVID-19 vaccine candidate tested preclinically at UAB poised for Phase 1 clinical study

A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer is poised for clinical testing to begin in December.

25 Nov 2020

New analytical method to detect the patulin toxin in foods by using antibodies

The University of Valencia and Spanish National Research Council have patented a method to detect the patulin toxin in foods by using antibodies.

25 Nov 2020

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

In a recent cutting-edge study, US researchers unveiled an anti-staphylococcal enterotoxin B monoclonal antibody that can be repurposed to target the cleavage site of the SARS-CoV-2 spike glycoprotein and, in turn, inhibit viral infection. Their findings are currently available on bioRxiv preprint server.

25 Nov 2020

Convalescent plasma therapy ineffective in treating severe COVID-19, study finds

A recent study based at a hospital in Buenos Aires, Argentina, found that convalescent plasma therapy for patients with severe COVID-19, and COVID-19-related pneumonia, was largely ineffective.

25 Nov 2020

SARS-CoV-2 spike protein antibodies can persist up to 200 days after symptom onset

Researchers report SARS-CoV-2 antibodies to the spike protein (S protein) can persist 200 days after symptom onset, but that antibodies to the nucleoprotein (N protein) can reduce much more rapidly.

25 Nov 2020

Is COVID-19 severity mediated by higher antibody response?

A new study indicates that patients with more severe COVID-19 have a stronger antibody response.

25 Nov 2020

Robust antibody response to SARS-CoV-2 can persist for eight months, study finds

A study conducted by researchers based in Italy suggests that SARS-CoV-2 induces durable and strong immunity in patients who had moderate to severe COVID-19.

25 Nov 2020

Study shows how high frequency sound waves could revolutionize ultrasound-driven chemistry

Researchers have revealed how high-frequency sound waves can be used to build new materials, make smart nanoparticles and even deliver drugs to the lungs for painless, needle-free vaccinations.

25 Nov 2020

Austrian study shows robust antibody response to SARS-CoV-2 for over 6 months

In the face of discouraging news about the resurgence of COVID-19, some reports offer hope of protection in the face of a robust and persistent immune response. In an encouraging report, an Austrian preprint appearing on the medRxiv server in November 2020 suggests a high level of durable immunity to SARS-CoV-2 over at least six months.

24 Nov 2020

Protection of upper respiratory tract will require vaccines that mimic natural infection by SARS-CoV-2

Recently, a team of researchers studied the transmission modes of SARS-CoV-2 and the protection against re-infection in ferret models in work published on the preprint server, bioRxiv.

24 Nov 2020

Mild COVID-19 disease may trigger long-term immunity

Researchers in the United States have conducted a study showing that individuals who have recovered from mild coronavirus disease 2019 (COVID-19) developed sustained protective immune memory against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

24 Nov 2020

Sex steroids may play a protective role in COVID-19, shows study

A new paper from a UIC researcher shows evidence that suggests sex steroids may play a role in protecting against COVID-19 symptoms.

24 Nov 2020

The role of micro-RNA in SARS-CoV-2 infection and COVID-19

A team of researchers based in Iran have explored the role of micro-RNA in COVID-19. Their study titled, “The emerging role of microRNAs in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection,” was published in the latest issue of the journal International Immunopharmacology.

24 Nov 2020

Researchers recommend antibody cocktail to tackle SARS-CoV-2 mutations

A new study released on the medRxiv* preprint server indicates that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic – is developing multiple mutations that affect neutralization by antibodies.

24 Nov 2020

Biosensor assay SARS-CoV-2 antibody test may predict COVID-19 severity in patients

Researchers in New York, USA, have found an association of mortality with an early humoral response to SARS-CoV-2 infection within the first few days after onset of symptoms (DAOS), using a highly sensitive and automated testing-on-a-probe (TOP) biosensor assays for SARS-CoV-2.

24 Nov 2020

FairJourney Biologics and IONTAS sign agreement with Pandion Therapeutics to discover antibodies

FairJourney Biologics S.A (FJB) and IONTAS Limited, leaders in the discovery and optimization of VHH and fully human antibodies, today announced they have signed an agreement to discover antibodies with Pandion Therapeutics.

24 Nov 2020

Early high-titer convalescent plasma prevents 75% of severe COVID-19 in elderly

A promising new clinical study published on the preprint server medRxiv reports that if convalescent plasma with a high titer of antibodies is given early in the course of COVID-19 in elderly patients, the risk of severe illness is reduced by 73%.

24 Nov 2020

First checkpoint inhibitor vaccine shown to be safe, effective in colon cancer animal model

A study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute described a potential therapeutic anticancer vaccine that frees suppressed cancer-killing immune cells, enabling them to attack and destroy a tumor.

23 Nov 2020

Duke-NUS expert joins international taskforce to study the origins of SARS-CoV-2 virus

Nearly a year since the world first learned of the novel coronavirus disease 2019, COVID-19, many questions remain about SARS-CoV-2, the virus behind this pandemic: Where did it come from, how did it spread so widely and rapidly, and how can we stop similar outbreaks in the future?

23 Nov 2020

Antibodies News and Research

Early interferon therapy may mitigate COVID-19 severity

COVID-19 vaccine candidate tested preclinically at UAB poised for Phase 1 clinical study

New analytical method to detect the patulin toxin in foods by using antibodies

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

Convalescent plasma therapy ineffective in treating severe COVID-19, study finds

SARS-CoV-2 spike protein antibodies can persist up to 200 days after symptom onset

Is COVID-19 severity mediated by higher antibody response?

Robust antibody response to SARS-CoV-2 can persist for eight months, study finds

Study shows how high frequency sound waves could revolutionize ultrasound-driven chemistry

Austrian study shows robust antibody response to SARS-CoV-2 for over 6 months

Protection of upper respiratory tract will require vaccines that mimic natural infection by SARS-CoV-2

Mild COVID-19 disease may trigger long-term immunity

Sex steroids may play a protective role in COVID-19, shows study

The role of micro-RNA in SARS-CoV-2 infection and COVID-19

Researchers recommend antibody cocktail to tackle SARS-CoV-2 mutations

Biosensor assay SARS-CoV-2 antibody test may predict COVID-19 severity in patients

FairJourney Biologics and IONTAS sign agreement with Pandion Therapeutics to discover antibodies

Early high-titer convalescent plasma prevents 75% of severe COVID-19 in elderly

First checkpoint inhibitor vaccine shown to be safe, effective in colon cancer animal model

Duke-NUS expert joins international taskforce to study the origins of SARS-CoV-2 virus

Antibodies eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News